Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT01117428 Completed - Clinical trials for Metastatic Colorectal Cancer

Sym004 in Patients With Advanced Solid Tumors

Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.

NCT ID: NCT01109615 Terminated - Clinical trials for Metastatic Colorectal Cancer

Pemetrexed and Gemcitabine for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

PG
Start date: April 2010
Phase: Phase 2
Study type: Interventional

This study aims to investigate the efficacy and safety of the combination of pemetrexed and gemcitabine in heavily pre-treated, chemotherapy resistant colorectal cancer patients with KRAS mutations.

NCT ID: NCT01103323 Completed - Clinical trials for Metastatic Colorectal Cancer

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

Start date: April 2010
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled multi-center phase III study to evaluate efficacy and safety of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed on/after all approved drugs for CRC

NCT ID: NCT01085331 Completed - Clinical trials for Metastatic Colorectal Cancer

MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)

Start date: March 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The research trial is testing the experimental treatment MSC1936369B in combination with FOLFIRI, as second-line treatment in metastatic K Ras mutated colorectal cancer subjects. The study will be run in two parts: Part 1, or Safety Run-in Part: Will determine the maximum tolerated dose and the recommended Phase II dose (RP2D) of MSC1936369B combined with FOLFIRI as second-line treatment in subjects with metastatic K Ras mutated colorectal cancer. Part 2 or Phase II Randomised Part: Will assess the anti-tumor activity of MSC1936369B combined with FOLFIRI compared to FOLFIRI with placebo as second-line treatment in metastatic K Ras mutated colorectal cancer subjects.

NCT ID: NCT01075048 Completed - Clinical trials for Metastatic Colorectal Cancer

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Start date: January 26, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

ARQ 197 or placebo in combination with irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC), in participants with wild-type KRAS alleles who have failed front-line systemic therapy, to evaluate the safety, tolerability, and efficacy of ARQ 197, define the recommended dose for Phase 2. After the recommended dose is determined for Phase 2, participants receive study drug or placebo with irinotecan and cetuximab.

NCT ID: NCT01067053 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients.

BECOX
Start date: November 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether bevacizumab, capecitabine and oxaliplatin are an effective and safe first line of treatment for elderly patients with metastatic colorectal adenocarcinoma.

NCT ID: NCT01053104 Completed - Clinical trials for Metastatic Breast Cancer

Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring

DATACAP
Start date: November 2009
Phase: N/A
Study type: Observational

To develop a system to manage side effects and adjust chemotherapy dose such that a patient can receive their personal maximum tolerated dose.

NCT ID: NCT01051167 Completed - Clinical trials for Metastatic Colorectal Cancer

Bi-weekly Cetuximab Combined With 5-fluorouracil/Leucovorin/Oxaliplatin (FOLFOX-6) in Metastatic Colorectal Cancer

CEBIFOX
Start date: February 2009
Phase: Phase 2
Study type: Interventional

Cetuximab is normally given as a weekly schedule in the therapy of patients with metastatic colorectal cancer. In order to improve the convenience for the patients in first line-therapy this study will evaluate the efficacy and safety of a bi-weekly combination of cetuximab with FOLFOX.

NCT ID: NCT01040000 Completed - Clinical trials for Metastatic Colorectal Cancer

QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Start date: January 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the phase 2 component of this study is to determine if giving the immune molecule NPC-1C to individuals who have cancer of the pancreas or gastrointestinal tract (colon or rectum) which has not responded to standard treatments can shrink or halt the growth of cancer, and to obtain additional data to study its effect on the immune system. Safety data will also be accumulated and evaluated during this study. NPC-1C is a monoclonal antibody that recognizes a specific tumor target on certain cancers. In laboratory studies, the antibody killed tumor cells in some colon and pancreatic cancers that express the NPC-1C antigen by a process called "antibody-dependent cell cytotoxicity" or ADCC.

NCT ID: NCT01039506 Completed - Clinical trials for Metastatic Colorectal Cancer

An Observational Study of CPT-11 Based Regimens and UGT1A1 Genotypes in Metastatic Colorectal Cancer (mCRC)

Start date: October 15, 2009
Phase:
Study type: Observational

The purpose of this study is to examine the correlation between UGT1A1 genotypes and the efficacy of CPT-11 based regimens (FOLFIRI, CPT-11+S-1, CPT-11) for patients with metastatic colorectal cancer.